Core Viewpoint - Junsei Biotech has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] Company Overview - Junsei Biotech focuses on innovative cell therapies and drug development for solid tumors, aiming to create safer, more effective, and affordable immunotherapy options [3] - The company's core product, GC101, is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepletion or IL-2 administration, potentially becoming the first TIL therapy approved in China [3][4] - GC101 has shown objective response rates of 30% in advanced melanoma and 41.7% in advanced non-small cell lung cancer patients who failed standard treatments [4] Financial Performance - Revenue for the fiscal years ending June 30, 2023, 2024, and 2025 was recorded at RMB 6.812 million, RMB 3.372 million, and RMB 6.830 million, respectively [5] - The company reported losses of RMB 94.391 million, RMB 163.652 million, and RMB 97.580 million for the same periods [6][7] Industry Overview - The global oncology drug market is projected to grow to USD 253.3 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% from 2020 to 2024 [8] - The Chinese oncology drug market is expected to reach RMB 258.2 billion in 2024, with a CAGR of 6.9% from 2020 to 2024 [11] - The TIL therapy market is anticipated to grow significantly, reaching USD 1.04 billion in 2024 and USD 16.92 billion by 2030, with a CAGR of 59.3% from 2024 to 2028 [14][17] Clinical and Regulatory Landscape - The TIL therapy market is expected to expand rapidly due to clinical, technical, regulatory, and funding support, with promising results in various solid tumors [17] - GC101 is currently undergoing critical Phase II clinical trials for melanoma and is in Phase I for non-small cell lung cancer, with plans to submit a Biologics License Application (BLA) by 2026 [4]
新股消息 | 君赛生物递表港交所 致力于实体瘤创新细胞疗法与创新药开发
智通财经网·2025-12-10 11:14